Literature DB >> 28158479

Acute Respiratory Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study.

Yao-Chun Wen1, Fei-Yuan Hsiao1,2,3, K Arnold Chan4,5, Zhen-Fang Lin1,2,3, Li-Jiuan Shen1,2,3, Cheng-Chung Fang6.   

Abstract

Background: Previous studies have suggested that acute respiratory infection (ARI) and nonsteroidal anti-inflammatory drugs (NSAIDs) use could trigger acute myocardial infarction (AMI). In some countries, physicians prescribe NSAIDs for patients with ARI for symptom relief. However, there is no research evaluating whether NSAIDs use during ARI episodes may increase the risk of AMI.
Methods: We identified 9793 patients with an incident hospitalization of AMI (index date) between 2007 and 2011. Using case-crossover design, we compared the following exposure status between the case (1-7-day before index date) and matched control period (366-372-day before index date): NSAIDs use during ARI episodes, ARI episodes without NSAIDs use, NSAIDs use only, or no exposure. Multivariable conditional logistic regression models were used to estimate odds ratios adjusted for potential confounders.
Results: Nonsteroidal anti-inflammatory drugs use during ARI was associated with a 3.4-fold increased risk of AMI (adjusted odds ratio [aOR] = 3.41; 95% confidence interval [CI] = 2.80-4.16), ARI without NSAIDs use was associated with a 2.7-fold increased risk (aOR = 2.65; 95% CI = 2.29-3.06), and NSAIDs use only was associated with a 1.5-fold increased risk (aOR = 1.47; 95% CI = 1.33-1.62). Moreover, parenteral NSAIDs were associated with much higher risk in ARI patients (aOR = 7.22; 95% CI = 4.07-12.81). Conclusions: Nonsteroidal anti-inflammatory drugs use during ARI episodes, especially parenteral NSAIDs, was associated with a further increased risk of AMI.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  acute myocardial infarction (AMI); acute respiratory infection (ARI); nonsteroidal anti-inflammatory drugs (NSAIDs); case-crossover study

Mesh:

Substances:

Year:  2017        PMID: 28158479     DOI: 10.1093/infdis/jiw603

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study.

Authors:  Muhammad B Malik; Samar A Amer; Eric Merrell; Ronald Russo; Jeffrey B Riley; Austin Scro; Elizabeth James; Anderson Anuforo; Soumya Adhikari; Rosalie Siciliano; Philip Chebaya; Edward Darling; Michael Kuhn; Gary Nieman; Ahmed Shawkat; Hani Aiash
Journal:  Health Sci Rep       Date:  2022-07-11

2.  Hsa_circ_0007059 promotes apoptosis and inflammation in cardiomyocytes during ischemia by targeting microRNA-378 and microRNA-383.

Authors:  Chaorui Xu; Zhuowen Jia; Xuefei Cao; Sha Wang; Jipeng Wang; Liping An
Journal:  Cell Cycle       Date:  2022-02-22       Impact factor: 5.173

Review 3.  The role of adjuvant immunomodulatory agents for treatment of severe influenza.

Authors:  David S Hui; Nelson Lee; Paul K Chan; John H Beigel
Journal:  Antiviral Res       Date:  2018-01-08       Impact factor: 5.970

4.  Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland.

Authors:  Charlotte Warren-Gash; Ruth Blackburn; Heather Whitaker; Jim McMenamin; Andrew C Hayward
Journal:  Eur Respir J       Date:  2018-03-29       Impact factor: 16.671

5.  COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.

Authors:  Joseph V Pergolizzi; Giustino Varrassi; Peter Magnusson; Jo Ann LeQuang; Antonella Paladini; Robert Taylor; Charles Wollmuth; Frank Breve; Paul Christo
Journal:  Pain Ther       Date:  2020-05-24

Review 6.  Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management.

Authors:  Benedikt Preckel; Marcus J Schultz; Alexander P Vlaar; Abraham H Hulst; Jeroen Hermanides; Menno D de Jong; Wolfgang S Schlack; Markus F Stevens; Robert P Weenink; Markus W Hollmann
Journal:  J Clin Med       Date:  2020-05-15       Impact factor: 4.241

7.  Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19.

Authors:  Jungchan Park; Seung-Hwa Lee; Kwangmo Yang; Seng Chan You; Jinseob Kim
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

Review 8.  Impact of repurposed drugs on the symptomatic COVID-19 patients.

Authors:  Iqbal Hussain; Afzal Hussain; Mohamed F Alajmi; Md Tabish Rehman; Samira Amir
Journal:  J Infect Public Health       Date:  2020-12-07       Impact factor: 3.718

Review 9.  Emerging treatment strategies for COVID-19 infection.

Authors:  Maria Gavriatopoulou; Ioannis Ntanasis-Stathopoulos; Eleni Korompoki; Despina Fotiou; Magdalini Migkou; Ioannis-Georgios Tzanninis; Theodora Psaltopoulou; Efstathios Kastritis; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Clin Exp Med       Date:  2020-10-30       Impact factor: 3.984

Review 10.  Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR.

Authors:  Lai-Shan Tam; Yoshiya Tanaka; Rohini Handa; Chi-Chen Chang; Yew Kuang Cheng; Nazrul Isalm; Mengtao Li; Jose Paulo Lorenzo; Yeong-Wook Song; Kazuhiko Yamamoto; Xiaofeng Zeng; Syed Atiqul Haq
Journal:  Int J Rheum Dis       Date:  2020-05-27       Impact factor: 2.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.